Annual report pursuant to Section 13 and 15(d)

Intangible Assets (Tables)

v3.20.4
Intangible Assets (Tables)
12 Months Ended
Sep. 30, 2020
Intangible Assets  
Schedule of intangible assets

The Company’s intangible assets consisted of the following:

 

 

 

 

 

 

 

 

 

    

As of September 30, 

 

 

2020

 

2019

Clinical trial data

 

$

250,000

 

$

250,000

Accumulated amortization

 

 

(250,000)

 

 

(104,167)

Intangible assets, net

 

$

 —

 

$

145,833